Review
Engineering, Biomedical
Xinyi Zhang, Hengqing Cui, Wenjun Zhang, Zhaoshen Li, Jie Gao
Summary: Tumor vaccination is a promising approach for tumor immunotherapy. Whole tumor cells, extracellular vesicles, and cell membrane-encapsulated nanoparticles can be used as tumor cell-derived vaccines to trigger comprehensive tumor-specific immune responses. However, engineering improvements are needed to enhance their immunogenicity and targeting. Further research and advances in materials science, biomedicine, and oncology can facilitate the clinical translation of tumor cell-derived vaccines.
BIOACTIVE MATERIALS
(2023)
Article
Oncology
Yue Liu, Joanna Pagacz, Donald J. Wolfgeher, Kenneth D. Bromerg, Jacob Gorman, Stephen J. Kron
Summary: Antigen presentation may be the limiting factor in the low immune response to radiation therapy, and combining immune checkpoint blockade does not restore cytotoxic T lymphocytes function. Therapeutic vaccines based on senescent tumor cells or SnC-activated dendritic cells have the potential to enhance immune therapies and limit recurrence or metastasis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Chemistry, Multidisciplinary
Wen-Hao Li, Jing-Yun Su, Yan-Mei Li
Summary: Cancer vaccines aim to enhance tumor-specific immune responses by engaging both T-cell and B-cell immunity. Different factors, including antigen selection, immune activation, vaccine delivery, and repeatable vaccination, should be considered for the rational design of therapeutic cancer vaccines. Chemical strategies such as adjuvants and nanomaterials play crucial roles in advancing the development of effective T-cell- and B-cell-based cancer vaccines.
ACCOUNTS OF CHEMICAL RESEARCH
(2022)
Review
Medicine, Research & Experimental
Yingxue Mei, Xiang Wang
Summary: RNA modification refers to chemically altered nucleotides and is widely present in diverse natural RNAs, closely related to RNA structure and function. mRNA-based vaccines have gained attention and rapid development as novel weapons against diseases, including cancer. The success of RNA vaccines in clinical application is largely due to innovative methods, such as incorporating modified nucleotides into synthetic RNA. Selecting optimal RNA modifications to reduce instability and immunogenicity of RNA molecules is critical for improving the efficacy and safety of mRNA vaccines. This review summarizes the functions of RNA modifications and their application in mRNA vaccines, highlights recent advances in mRNA vaccines for cancer immunotherapy, and provides perspectives for future development in personalized tumor therapy.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
David Reparaz, Marta Ruiz, Diana Llopiz, Leyre Silva, Enric Vercher, Belen Aparicio, Josune Egea, Ibon Tamayo-Uria, Sandra Hervas-Stubbs, Jorge Garcia-Balduz, Carla Castro, Mercedes Inarrairaegui, Maria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, Luigi Buonaguro, Charlotte Rohrer, Kathrin Heim, Catrin Tauber, Maike Hofmann, Robert Thimme, Bruno Sangro, Pablo Sarobe
Summary: Immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies may be generated in hepatocellular carcinoma tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Long Chen, Hao Qin, Ruifang Zhao, Xiao Zhao, Liangru Lin, Yang Che, Yixuan Lin, Yao Li, Yuting Qin, Yiyi Li, Shaoli Liu, Keman Cheng, Hanqing Chen, Jian Shi, Gregory J. Anderson, Yan Wu, Yuliang Zhao, Guangjun Nie
Summary: Utilizing Escherichia coli cytoplasmic membranes as adjuvants, a vaccine based on hybrid membrane nanoparticles containing tumor cell membranes induced sufficient antitumor reactivity without notable adverse effects, showing efficacy in various tumor mouse models and providing long-term protection against tumor rechallenge.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Review
Immunology
Xiaoyu Xue, Rui Li, Zhenni Chen, Guiyu Li, Bisheng Liu, Shanshan Guo, Qianhua Yue, Siye Yang, Linlin Xie, Yiguan Zhang, Junning Zhao, Ruirong Tan
Summary: The relationship between the gut microbiota and cancer immunology is complex and plays a critical role in tumor occurrence, progression, and treatment. The symbiotic microecosystem formed by the gut microbiota, metabolome, and host immunome is fundamental for the analysis of tumor pathogenesis and the development of therapeutic strategies for cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Renee N. Donahue, Jennifer L. Marte, Meghali Goswami, Nicole J. Toney, Yo-Ting Tsai, James L. Gulley, Jeffrey Schlom
Summary: This review discusses the effectiveness of vaccines against SARS-CoV-2, the ability of immune cells to lyse infected cells, and how a flow-based assay can detect various cell subsets. It also covers the impact of age on immune cell subsets, differences in immunomes between healthy donors and cancer patients, and the use of steroids in managing autoimmune adverse events and SARS-CoV-2 infections.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Editorial Material
Oncology
Gabriela Bindea, Bernhard Mlecnik, Jerome Galon
Summary: The complex dynamics of tumor-immune interaction during tumor progression have been studied using genomic and proteomic experiments. The Immunome, a compendium of markers for immune cell subpopulations, is used to describe the immune landscape in cancer. The immune contexture plays a crucial role in the success of cancer immunotherapy.
Editorial Material
Engineering, Biomedical
Andrew Redenti, Jaeseung Hahn, Tal Danino
Summary: Flagellated bacteria coated with antigen-adsorbing nanoparticles can induce systemic antitumour immune responses by transporting tumour antigens towards the tumour periphery, where they are taken up by functional antigen-presenting cells.
NATURE BIOMEDICAL ENGINEERING
(2022)
Review
Pharmacology & Pharmacy
Jeroen Heuts, Wim Jiskoot, Ferry Ossendorp, Koen van der Maaden
Summary: Cationic nanoparticles have shown to be effective in cancer immunotherapy by delivering tumor-associated antigens to dendritic cells and inducing strong antigen-specific cellular immune responses. Lipid- and polymer-based cationic nanoparticles are utilized for different types of cancer vaccines, and their potential in T-cell induction is discussed for therapeutic cancer vaccination.
Article
Oncology
Alessio Amatu, Arianna Pani, Giorgio Patelli, Oscar M. Gagliardi, Marina Loparco, Daniele Piscazzi, Andrea Cassingena, Federica Tosi, Silvia Ghezzi, Daniela Campisi, Renata Grifantini, Sergio Abrignani, Salvatore Siena, Francesco Scaglione, Andrea Sartore-Bianchi
Summary: This study evaluated the seroconversion rate of anti-spike antibodies in solid tumor patients after receiving SARS-CoV-2 mRNA vaccines and found a lower conversion rate in cancer patients. Age and treatment type also had an impact on the conversion rate. It is suggested to consider enhanced vaccination strategies for this group of patients and closely monitor SARS-CoV-2 infection during treatment.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Chemistry, Multidisciplinary
Yiran Zheng, Zhiyuan Zhong
Summary: Cancer vaccines have become powerful and clinically viable therapeutic modalities for reducing tumor burden, eradicating residual cancer cells, and preventing relapse. Recent years have seen rapid advancements in next-generation cancer vaccines, with cutting-edge technologies focused on eliciting robust and durable immune responses specific to cancer, as well as reducing systemic side effects. This perspective highlights innovative strategies such as high-throughput screening for neoantigens and optimal delivery systems, knowledge-based de novo design of effective delivery platforms with tissue-targeting specificity, and synergizing cancer vaccines with clinical immunotherapeutic practices like CAR-T and anti-PD-1 therapies.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Chemistry, Multidisciplinary
Jing Liu, Si Si Liew, Jun Wang, Kanyi Pu
Summary: Cancer vaccines aim to stimulate tumor-specific immune responses while sparing normal tissues, with bioinspired materials and technologies playing a role in reshaping the field of cancer nanomedicine. By mimicking desirable properties in nature, bioinspired engineering of cancer vaccine delivery platforms can enhance therapeutic efficacy and safety profiles for clinical translation.
ADVANCED MATERIALS
(2022)
Review
Immunology
Wenqing Jia, Tao Zhang, Haiyan Huang, Haoran Feng, Shaodong Wang, Zichao Guo, Zhiping Luo, Xiaopin Ji, Xi Cheng, Ren Zhao
Summary: This review provides a brief summary of different categories of colorectal cancer (CRC) vaccines and presents current outcomes of relevant clinical trials. It particularly focuses on recent advances in nanovaccines and neoantigen vaccines, which represent the trend and emphasis in CRC vaccine development.
FRONTIERS IN IMMUNOLOGY
(2022)
